Technologies

Almost 50 % of type one diabetics and about 33 % of type 2 diabetics will develop a pancreatic insufficiency in the course of their disease.

It is often difficult to differentiate patients with inflammatory bowel disease (IBD) those who suffer from irritable bowel syndrome due to similar symptoms of patients. Both groups show similar [...]

According to the Robert Koch Institute (RKI) every year 63.000 people in Germany fall ill with colon cancer. Approximately 25,000 people die annually from the consequences of this disease. Colon [...]

TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as [...]

Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.

Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.

The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).

Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.

Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]

RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma.